Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nimish Shah

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Nature Communications|January 25, 2022
Hyperpolarised <sup>13</sup>C-MRI identifies the emergence of a glycolytic cell population within intermediate-risk human prostate cancerNikita Sushentsev, Mary A McLean, Anne Y Warren, et al.
Nature Communications|March 8, 2022
Author Correction: Hyperpolarised <sup>13</sup>C-MRI identifies the emergence of a glycolytic cell population within intermediate-risk human prostate cancerNikita Sushentsev, Mary A McLean, Anne Y Warren, et al.
Leukemia|January 6, 2024
Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potentialChunye Zhang, Ellen Stelloo, Sharon Barrans, et al.
Blood Advances|April 29, 2026
Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC studyToby A Eyre, Nicolás Martínez-Calle, Shankara Paneesha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2025
Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT StudyJoanna A Krupka, Ilias Moutsopoulos, Natasha H Cutmore, et al.
Blood Advances|January 12, 2022
Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCLMichael Northend, William Wilson, Wendy Osborne, et al.
Haematologica|May 14, 2026
Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencingWendy Osborne, Euan Haynes, William Wilson, et al.
Blood|January 7, 2022
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patientsMatthew R Wilson, Toby A Eyre, Amy A Kirkwood, et al.
Leukemia|July 11, 2020
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL CampusLydia Scarfò, Thomas Chatzikonstantinou, Gian Matteo Rigolin, et al.
Blood Advances|April 14, 2026
Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analysesJamie E Flerlage, Dennis A Eichenauer, Michael Fuchs, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Nature Communications|January 25, 2022
Hyperpolarised <sup>13</sup>C-MRI identifies the emergence of a glycolytic cell population within intermediate-risk human prostate cancerNikita Sushentsev, Mary A McLean, Anne Y Warren, et al.
Nature Communications|March 8, 2022
Author Correction: Hyperpolarised <sup>13</sup>C-MRI identifies the emergence of a glycolytic cell population within intermediate-risk human prostate cancerNikita Sushentsev, Mary A McLean, Anne Y Warren, et al.
Leukemia|January 6, 2024
Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potentialChunye Zhang, Ellen Stelloo, Sharon Barrans, et al.
Blood Advances|April 29, 2026
Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC studyToby A Eyre, Nicolás Martínez-Calle, Shankara Paneesha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2025
Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT StudyJoanna A Krupka, Ilias Moutsopoulos, Natasha H Cutmore, et al.
Blood Advances|January 12, 2022
Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCLMichael Northend, William Wilson, Wendy Osborne, et al.
Haematologica|May 14, 2026
Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencingWendy Osborne, Euan Haynes, William Wilson, et al.
Blood|January 7, 2022
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patientsMatthew R Wilson, Toby A Eyre, Amy A Kirkwood, et al.
Leukemia|July 11, 2020
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL CampusLydia Scarfò, Thomas Chatzikonstantinou, Gian Matteo Rigolin, et al.
Blood Advances|April 14, 2026
Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analysesJamie E Flerlage, Dennis A Eichenauer, Michael Fuchs, et al.
Pageof 8